Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marcel Reiser

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Blood|October 27, 2007
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Martin Dreyling, Wolfram Klapper, et al.
Annals of Neurology|March 13, 2010
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphomaAnnika Juergens, Hendrik Pels, Sabine Rogowski, et al.
Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 19, 2008
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseasesMichael Hertl, Detlef Zillikens, Luca Borradori, et al.
Blood|August 27, 2005
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupWolfgang Hiddemann, Michael Kneba, Martin Dreyling, et al.
The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.
Blood|November 10, 2021
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemiaPetra Langerbeins, Can Zhang, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2014
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lungHans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Blood|October 27, 2007
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphomaEva Hoster, Martin Dreyling, Wolfram Klapper, et al.
Annals of Neurology|March 13, 2010
Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphomaAnnika Juergens, Hendrik Pels, Sabine Rogowski, et al.
Blood|June 20, 2026
Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trialArmin Riecke, Sandra Robrecht, Deyan Yordanov Yosifov, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|January 19, 2008
Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseasesMichael Hertl, Detlef Zillikens, Luca Borradori, et al.
Blood|August 27, 2005
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupWolfgang Hiddemann, Michael Kneba, Martin Dreyling, et al.
The Lancet. Oncology|January 30, 2008
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)Michael Pfreundschuh, Joerg Schubert, Marita Ziepert, et al.
Blood|November 10, 2021
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemiaPetra Langerbeins, Can Zhang, Sandra Robrecht, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 11, 2014
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lungHans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Lung Cancer (Amsterdam, Netherlands)|December 28, 2020
Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)Frank Griesinger, Wilfried Eberhardt, Arnd Nusch, et al.
Pageof 8